Important News
Qurgen real-time updates on corporate news, industry trends and exciting events, witnessing every step of growth.
Important News
A non-small cell lung cancer patient who received SON-DP for 4 months has achieved a complete response in February 2025. By March 2026, a 14-month follow-up reported that the patient continued to maintain a complete remission.
The China CDE officially approved the investigational new drug application of Suzhou Fuent Pharmaceutcal Co., Ltd., with the CDE acceptance number: CXSL2400508.
Qurgen has successfully manufactured two batches of GMP-scale SON-DP anti-tumor transcription factor protein drug. These batches of the manufactured SON-DP drug met the FDA protein drug quality standard and have been used in the US and China Phase I clinical trials.
The 3,000-square-meter clinical drug manufacturing center of Suzhou Fuent Pharmaceutical Co., Ltd. has been officially completed.